Save on Galcanezumab-GNLM with Coupons, Discounts & Savings Programs

Galcanezumab-GNLM is available as one of the following subcutaneous injections:

• 120 mg/mL solution in a single-dose prefilled pen
• 120 mg/mL solution in a single-dose prefilled syringe
• 100 mg/mL solution in a single-dose prefilled syringe

Galcanezumab-GNLM is a monoclonal antibody and is used for the following:

• Migraine prevention
• Episodic (occasional) cluster headaches

Galcanezumab-GNLM is a monoclonal antibody. It blocks a protein in your body called calcitonin gene-related peptide (CGRP) ligand. Your nerves release CGRPs during migraine attacks and cluster headaches. CGRPs cause the blood vessels in your brain to swell, which can lead to pain. When Galcanezumab-GNLM blocks these proteins, it can prevent migraines and ease pain from cluster headaches.

Galcanezumab-GNLM is dosed as following:

• Migraine prevention: The typical dose is 240 mg (two injections of 120 mg each, one right after the other) injected under the skin once when you first start the medication. Then, inject 120 mg under the skin once a month
• Episodic cluster headaches: The typical dose is 300 mg (three injections of 100 mg each, one right after the other) injected under the skin once at the start of your cluster period. Then, inject 300 mg under the skin once a month, until the end of your cluster period

Galcanezumab-GNLM is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Galcanezumab-GNLM:

• Pain, itching, warmth, and other injection site reactions
• Sore throat, runny nose
• Back pain

Serious side effects are rare with Galcanezumab-GNLM. Contact your healthcare provider immediately if you experience any of the following.

• Serious allergic reactions: hives, swelling in the face and eyes, swollen throat, trouble breathing, wheezing, nausea, vomiting, diarrhea, dizziness, fainting

There are no major drug interactions listed for Galcanezumab-GNLM. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

There are no adequate data on the developmental risk associated with the use of Galcanezumab-GNLM in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Galcanezumab-GNLM during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-464-4724 or by contacting the company at Migraine pregnancy registry

• Emgality